Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > OVs improve cancer immunotherapy by reprogramming TME

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 11, 2023 10:45am

136 Views

Post# 35777786

RE:RE:RE:RE:OVs improve cancer immunotherapy by reprogramming TME

The adenovirus LOAd703 is administered by intratumoral (IT) injection. I guess you haven't read what I've posted on this matter in the past, before you mounted your attack, and obviously don't know that Big Pharma won't touch IT administered drugs because of the complexity of requiring extensive prep time and the use of surgical suites to deliver that form of drug. That's just one of many things that you seem to have overlooked before posting your well defined 'myopic' view.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record